These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35648149)

  • 21. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
    Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.
    Mao J; Martin I; McLeod J; Nolan G; van Horn R; Vourvahis M; Lin YS
    Drug Metab Rev; 2017 Feb; 49(1):18-34. PubMed ID: 27718639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
    Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
    J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity.
    Taya Y; Mizunaga M; Nakao S; Jutanom M; Shimizu N; Nomura Y; Nakagawa K
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil.
    Rodrigues AD; Wood LS; Vourvahis M; Rowland A
    Clin Pharmacol Ther; 2022 Feb; 111(2):425-434. PubMed ID: 34623637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
    de Graan AJ; Sparreboom A; de Bruijn P; de Jonge E; van der Holt B; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
    Br J Clin Pharmacol; 2015 Sep; 80(3):560-8. PubMed ID: 26119961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene Polymorphisms of NLRP3 Associated With Plasma Levels of 4β-Hydroxycholesterol, an Endogenous Marker of CYP3A Activity, in Patients With Asthma.
    Hirai K; Kimura T; Suzuki Y; Shimoshikiryo T; Shirai T; Itoh K
    Clin Pharmacol Ther; 2024 Jul; 116(1):147-154. PubMed ID: 38482940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.
    Diczfalusy U; Miura J; Roh HK; Mirghani RA; Sayi J; Larsson H; Bodin KG; Allqvist A; Jande M; Kim JW; Aklillu E; Gustafsson LL; Bertilsson L
    Pharmacogenet Genomics; 2008 Mar; 18(3):201-8. PubMed ID: 18300941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy.
    Wide K; Larsson H; Bertilsson L; Diczfalusy U
    Br J Clin Pharmacol; 2008 May; 65(5):708-15. PubMed ID: 18279471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
    Ogasawara K; LoRusso PM; Olszanski AJ; Rixe O; Xu C; Yin J; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):87-95. PubMed ID: 32537715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.
    Thirumaran RK; Lamba JK; Kim RB; Urquhart BL; Gregor JC; Chande N; Fan Y; Qi A; Cheng C; Thummel KE; Hall SD; Schuetz EG
    Biochem Pharmacol; 2012 Jul; 84(1):104-12. PubMed ID: 22484315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recovery of CYP3A Phenotype after Kidney Transplantation.
    Hole K; Størset E; Olastuen A; Haslemo T; Kro GB; Midtvedt K; Åsberg A; Molden E
    Drug Metab Dispos; 2017 Dec; 45(12):1260-1265. PubMed ID: 28928137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative analysis of 4β- and 4α‑hydroxycholesterol in human plasma and serum by UHPLC/ESI-HR-MS.
    Hautajärvi H; Hukkanen J; Turpeinen M; Mattila S; Tolonen A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():179-186. PubMed ID: 30340067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity.
    Aubry AF; Dean B; Diczfalusy U; Goodenough A; Iffland A; McLeod J; Weng N; Yang Z
    AAPS J; 2016 Sep; 18(5):1056-1066. PubMed ID: 27350147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.
    Rowland A; Ruanglertboon W; van Dyk M; Wijayakumara D; Wood LS; Meech R; Mackenzie PI; Rodrigues AD; Marshall JC; Sorich MJ
    Br J Clin Pharmacol; 2019 Jan; 85(1):216-226. PubMed ID: 30340248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
    Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
    Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.
    Gebeyehu E; Engidawork E; Bijnsdorp A; Aminy A; Diczfalusy U; Aklillu E
    Pharmacogenomics J; 2011 Apr; 11(2):130-7. PubMed ID: 20231858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
    Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
    Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.
    Kapetas AJ; Sorich MJ; Rodrigues AD; Rowland A
    AAPS J; 2019 Jun; 21(5):78. PubMed ID: 31218462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
    Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
    Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.